15 Trending Stocks

Tue, Nov 24, 2020

Alexion Pharmaceuticals

ALXN 123.11
0.50 (0.4%)

Open: 122.66 High: 124.39 Low: 121.23

9 x 123.11 = 1107.99
x $123.11 =

NASDAQ: ALXN $27 Billion Large-Cap. Nasdaq 100. S&P 500. Health Care Sector. Biotech & Pharma Industry. 5 Year Return 32%. 1 Year Return 8%. 2020 YTD Return 14%. Since Earnings 7%.

ST

External Links

Free Channels & more...

For Starters

Charts

image
image

52WL $72.67

The 52 Week Low is $72.67 set on Mon, Mar 16, 2020.

52WH $128.19

The 52 Week High is $128.19 set on Mon, Nov 16, 2020.

ATH $208.88

The All-Time High is $208.88 set on Thu, Jul 23, 2015.

52 Week Range

$72.67
$128.19
Mar 16, 2020
Nov 16, 2020

Earnings

-4.84

Earnings Per Share

392.83

Price To Earnings Ratio


Q2 Earnings for Apr, May & Jun

Thu, Jul 30, 2020

Since Q2 Earnings Report

ALXN 17.7%


Q3 Earnings for Jul, Aug & Sep

Thu, Oct 29, 2020

Since Q3 Earnings Report

ALXN 7.2%

Dividends

0.00

Dividend Yield

0.00

Dividend Rate

--

Ex-Dividend Date

--

Dividend Payment Date

--

Dividend Frequency

0

Dividend History

Profile

Alexion Pharmaceuticals trades on the NASDAQ. ALXN's market cap is 26.6 Billion.

Alexion Pharmaceuticals specializes in developing and marketing drugs for rare, life-threatening medical conditions. Its blockbuster product, Soliris, is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Next-generation Ultomiris is approved in PNH and aHUS. Strensiq and Kanuma target ultrarare metabolic diseases. Alexion's pipeline targets rare diseases with high unmet need in hematology, nephrology, metabolic diseases, neurology, cardiology, and other areas.

Website

Related Channels

Account Channels

Track your portfolio and more.